Li Tian

Νo. 1 Jianshe East Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway.

Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway.

Journal: Gut
Published: August 03, 2024

Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma.

Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma.

Journal: Gut
Published: July 11, 2022

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: June 16, 2022

Chinese Clinical Ethicists Accept Physicians' Benevolent Deception of Patients.

Chinese Clinical Ethicists Accept Physicians' Benevolent Deception of Patients.

Journal: The American journal of bioethics : AJOB
Published: May 04, 2021

Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.

Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.

Journal: Hematological oncology
Published: February 15, 2021

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.

Journal: OncoTargets and therapy
Published: May 14, 2020

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.

Journal: Therapeutic advances in medical oncology
Published: December 26, 2019

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.

Journal: Journal of neuro-oncology
Published: March 25, 2018

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.

Journal: Journal of hematology & oncology
Published: December 12, 2017

Exploring relationships between first-line nurse manager's safety attitudes and safety factors in Henan, China.

Exploring relationships between first-line nurse manager's safety attitudes and safety factors in Henan, China.

Journal: Journal of nursing management
Published: August 15, 2017
Showing 1-10 of 10

Last Updated: 09/26/2026